Get the Stockscreener App
1.035
2.36%
-0.025
Pacific Biosciences Of California Inc stock is traded at $1.035, with a volume of 15.33M.
It is down -2.36% in the last 24 hours and down -13.75% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.06
Open:
$1.05
24h Volume:
15.33M
Relative Volume:
1.56
Market Cap:
$310.59M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-0.69
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
-7.59%
1M Performance:
-13.75%
6M Performance:
-35.11%
1Y Performance:
-52.74%
1-Day Range:
$0.9501
$1.06
1-Week Range:
$0.9501
$1.18
52-Week Range:
$0.9501
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.035 | 336.09M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Potential Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Not Without Risk - simplywall.st
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences - GuruFocus
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock N - GuruFocus
Where Pacific Biosciences Stands With Analysts - Benzinga
PACB Price Target Reduced by Piper Sandler Following Quarterly R - GuruFocus
Metagenomics Market Size, Share, Forecast & Trends Analysis Report 2025: Market to Soar to $6.71 Billion by 2031, Driven by Agri Genomics and Genome Mapping - GlobeNewswire Inc.
PacBio clears allegations after special investigation By Investing.com - Investing.com Canada
PACB Stock May Rise Following the Deal With Chulalongkorn University - Nasdaq
PacBio (PACB) Completes Probe into Employment Practices and Cybe - GuruFocus
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated - Yahoo Finance
Pacbio adjusts 2025 revenue guidance to $150M-$170M amid macroeconomic challenges - MSN
Pacific Biosciences of California First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings - GuruFocus
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates - Yahoo Finance
Pacific Biosciences of California Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript - Insider Monkey
Pacific Biosciences (PACB) Beats Revenue Expectations Amid ChallengesNews and Statistics - IndexBox
Pacific Biosciences of California Q1 2025 Earnings Call Transcript - MarketBeat
Pacific Biosciences: Q1 Earnings Snapshot - Norwalk Hour
PacBio Announces First Quarter 2025 Financial Results - GlobeNewswire
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Pacific Biosciences (PACB) Reports Q1 2025 Financials Amid Macroeconomic Challenges - GuruFocus
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1 - Yahoo Finance
PacBio Q1 2025 slides: Consumable growth offsets instrument revenue decline - Investing.com Canada
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
PacBio Reports Q1 2025 Financial Results, Announces Restructuring and Strategic Focus Shift - Nasdaq
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings | PACB Stock News - GuruFocus
Pacific Biosciences (PACB) Prepares for Q1 Earnings Announcement - GuruFocus
Earnings To Watch: Pacific Biosciences of California Inc (PACB) Reports Q1 2025 Result - GuruFocus
PacBio (PACB) Q1 Earnings: What To Expect - Yahoo Finance
Pacific Biosciences of California Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
PacBio (PACB) Launches Pioneering Genomic Project in Asia Pacific | PACB Stock News - GuruFocus
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
PacBio (PACB) Q4 Earnings Report Preview: What To Look For - Barchart.com
Pacific Biosciences of California (PACB) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Pacific Biosciences Says New Technology to Enhance HiFi Sequencing - marketscreener.com
PacBio Licenses CUHK AI Tech To Boost 5-Base Methylation Detection In HiFi Sequencing - Nasdaq
PacBio (PACB) Enhances Methylation Detection in HiFi Sequencing - GuruFocus
PacBio Licenses Advanced DNA Methylation Detection Technology to Enhance HiFi Sequencing Accuracy - Nasdaq
PACB stock touches 52-week low at $1.08 amid market challenges - Investing.com Australia
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know - Yahoo Finance
Pacific Biosciences of California Selected by Davos Alzheimer's Collaborative as Technology Partner - marketscreener.com
PacBio partners with global Alzheimer’s initiative By Investing.com - Investing.com India
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pacific Biosciences Of California Inc Stock (PACB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Van Oene Mark | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
6,486 |
9,126 |
1,497,695 |
| Farmer Michele | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
2,973 |
4,183 |
184,619 |
0.85%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):